Many European cities are experiencing significant increases in the number of patients seen in the intensive care units (ICUs) of their hospitals due to COVID-19, thus could reach their limit in the next few weeks, the director general of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, warned this Friday.
“Last week the number of cases reported in Europe was three times higher than during the first peak in the month of March “, added the head of the WHO, who has stressed that many people” understandably are exhausted “by the disruption that the pandemic is causing in their lives and work.
However, the WHO technical director for COVID-19, Maria Van Kerkhove, has stated that, despite the fact that the increase in cases and hospitalizations in Europe is worrying, not “the same position as six months ago”, because the knowledge about the disease is much greater.
“Diagnostic capacity has been increased, health workers are more trained and experienced, and there is public awareness of what must be done to protect oneself, so all this must be combined to help control the pandemic, “he stressed.
Defense of dexamethasone
Tedros has also stressed that the dexamethasone is, at the moment, the only treatment that has been proven effective in severe cases of COVID-19, hours after the WHO notified that the four therapies it was testing in the so-called ‘Solidarity Trials’, with thousands of patients around the world, have failed.
“In June we announced that we would discontinue the studies with hydroxychloroquine, in July it was reported that we would not use more patients for the lopinavir / ritonavir trials, and now the interim results show that the other two drugs in trials, remdesivir and interferon, have little or no effect in reducing deaths from COVID-19 “, has influenced the Ethiopian.
The CEO has stated that this does not spell the end of the ‘Solidarity Trials’, which continue to recruit around 2,000 patients each month for testing, and noted that they could be tested in the future. other treatments with monoclonal antibodies and other antivirals.